Show simple item record

dc.contributor.authorChedid, Marcio F.
dc.contributor.authorRodrigo Calabia, Emilio 
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2020-06-29T18:13:47Z
dc.date.available2020-06-29T18:13:47Z
dc.date.issued2019
dc.identifier.issn2373-8731
dc.identifier.urihttp://hdl.handle.net/10902/18840
dc.format.extent2 p.es_ES
dc.language.isoenges_ES
dc.publisherWolters Kluweres_ES
dc.rights© 2019 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc.es_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceTransplant Direct . 2019 Sep 23;5(10):e492es_ES
dc.titleBortezomib: A New Promising Therapy for Early Antibody-Mediated Rejection After Liver Transplantation?es_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersionhttps://www.doi.org/10.1097/TXD.0000000000000931es_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.1097/TXD.0000000000000931
dc.type.versionpublishedVersiones_ES


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2019 The  Author(s).  Transplantation  Direct.  Published  by  Wolters  Kluwer Health, Inc.Except where otherwise noted, this item's license is described as © 2019 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc.